MarketCap
Facebook
X
TelegramAnnual report 2025
added 11-25-2025
Becton, Dickinson and Company Financial Ratios 2011-2026 | BDX
Annual Financial Ratios Becton, Dickinson and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
33.5 | 37.6 | 45.6 | 37.7 | 34.2 | 79.8 | 56.0 | 191.6 | 41.5 | 36.6 | 41.5 | 20.8 | 15.9 | 13.2 | 13.9 |
P/S |
2.6 | 3.2 | 3.5 | 3.6 | 3.7 | 4.3 | 4.0 | 3.7 | 3.8 | 2.9 | 2.8 | 2.9 | 2.6 | 2.0 | 2.2 |
EPS |
5.8 | 5.9 | 5.0 | 5.9 | 6.9 | 2.8 | 4.0 | 0.6 | 4.7 | 4.6 | 3.4 | 6.1 | 6.6 | 5.7 | 5.8 |
EV (Enterprise Value) |
55.5 B | 62.4 B | 66.1 B | 66 B | 69.1 B | 66.8 B | 99.2 B | 91.3 B | 56.3 B | 52.1 B | 47.1 B | 30.2 B | 25.8 B | 21 B | 22 B |
EBITDA per Share |
17.5 | 16.2 | 15.4 | 15.8 | 15.5 | 10.8 | 16.6 | 16.3 | 13.3 | 15.4 | 11.8 | 11.2 | 9.23 | 10.1 | 10.3 |
EV/EBITDA |
13.6 | 20.1 | 19.6 | 18.9 | 17.2 | 14.0 | 16.8 | 12.3 | 12.6 | 8.7 | 8.4 | ||||
PEG |
3.01 | 15.15 | 24.9 | 5.48 | 8.99 | 61.08 | 0.1 | -2.21 | 17.33 | 1.08 | -0.94 | -2.76 | 0.97 | -13.63 | 5.99 |
P/B |
1.0 | 1.1 | 1.3 | 1.3 | 1.3 | 1.3 | 3.3 | 2.8 | 3.5 | 4.7 | 4.0 | 4.9 | 4.1 | 3.7 | 3.6 |
P/CF |
- | - | - | - | - | - | 29.1 | 30.2 | 25.1 | 19.4 | 26.3 | 22.6 | 22.4 | 12.8 | 15.9 |
ROE % |
6.61 | 6.59 | 5.75 | 7.04 | 8.84 | 3.68 | 5.85 | 1.48 | 8.50 | 12.78 | 9.70 | 23.45 | 25.64 | 28.29 | 26.32 |
ROA % |
3.03 | 2.98 | 2.81 | 3.36 | 3.88 | 1.62 | 2.38 | 0.58 | 2.92 | 3.81 | 2.59 | 9.52 | 10.64 | 10.30 | 12.19 |
ROCE % |
10.16 | 9.26 | 8.18 | 9.03 | 9.50 | 3.84 | 4.85 | 4.80 | 5.33 | 10.19 | 6.69 | 15.73 | 12.53 | 16.60 | 20.49 |
Current Ratio |
- | - | - | - | - | - | 1.2 | 1.0 | 5.6 | 1.4 | 1.4 | 2.7 | 2.8 | 2.7 | 2.6 |
DSO |
50.4 | 50.4 | 44.5 | 43.9 | 45.3 | 53.9 | 49.5 | 53.0 | 52.6 | 47.3 | 57.4 | 51.3 | 56.2 | 59.2 | 57.3 |
DIO |
118.5 | 117.5 | 105.8 | 104.8 | 95.4 | 104.7 | 104.6 | 102.6 | 107.9 | 96.6 | 128.0 | 131.6 | 131.8 | 120.6 | 121.6 |
DPO |
59.3 | 58.4 | 54.4 | 60.4 | 53.8 | 48.1 | 44.3 | 46.3 | 47.3 | 37.4 | 41.2 | 35.3 | 31.3 | 34.1 | 29.8 |
Operating Cycle |
168.9 | 167.8 | 150.4 | 148.7 | 140.7 | 158.6 | 154.1 | 155.5 | 160.5 | 144.0 | 185.4 | 182.9 | 188.0 | 179.8 | 178.9 |
Cash Conversion Cycle |
109.6 | 109.4 | 96.0 | 88.3 | 86.9 | 110.4 | 109.8 | 109.3 | 113.2 | 106.6 | 144.2 | 147.6 | 156.7 | 145.7 | 149.1 |
All numbers in USD currency
Quarterly Financial Ratios Becton, Dickinson and Company
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
2 | 1.07 | 1.05 | 1.68 | 1.85 | 0.97 | 1.37 | 1.54 | 1.71 | - | 1.18 | 1.51 | 2.3 | - | 1.73 | 0.95 | 3.38 | 0.36 | 0.98 | 3.38 | 0.88 | 0.46 | 1.53 | 0.88 | 2.09 | -0.64 | 2.08 | 2.09 | -0.76 | 1.27 | -0.75 | -0.76 | 2.64 | 0.09 | 1.83 | 2.64 | 1.08 | 0.86 | 0.3 | 1.08 | 1.22 | 1.56 | 1.69 | 1.22 | 1.4 | 6.16 | 1.55 | 1.4 | 3.18 | 4.24 | 1.62 | 3.18 | 1.23 | 4.36 | 1.57 | 1.23 |
EBITDA per Share |
4.45 | 3.28 | 3.66 | 3.33 | 3.8 | 3.45 | 3.2 | 3.5 | 4.06 | - | 3.13 | 3.21 | 4.35 | - | 6.01 | 2.69 | 6.18 | 10.3 | 5.05 | 6.18 | 3.8 | 12.4 | 6.48 | 3.8 | 5.39 | 9.2 | 5.06 | 5.39 | 2.29 | 8.51 | 1.36 | 2.26 | 5.04 | 10.2 | 5.09 | 5.04 | 3.03 | 6.79 | 1.97 | 3.03 | 2.53 | 8.35 | 3.71 | 2.53 | 2.68 | 8.1 | 3.44 | 2.68 | 2.65 | 7.48 | 3.51 | 2.65 | 2.19 | 3.99 | 0.92 | 2.31 |
ROE % |
6.56 | 6.40 | 6.29 | 6.65 | 6.56 | 6.47 | 5.36 | 5.64 | 5.70 | 6.50 | 6.83 | 9.00 | 8.42 | 7.50 | 8.04 | 7.07 | 10.03 | 7.27 | 7.51 | 8.44 | 5.54 | 7.03 | 5.61 | 6.30 | 7.84 | 4.40 | 7.57 | 3.72 | -0.18 | 7.87 | 5.59 | 11.72 | 20.13 | 15.89 | 18.17 | 13.93 | 9.76 | 11.25 | 14.68 | 20.26 | 21.74 | 22.42 | 40.31 | 39.85 | 40.65 | 49.30 | 46.74 | 48.66 | 58.31 | 49.89 | 48.70 | 47.90 | 38.23 | 20.11 | 7.11 | 5.45 |
ROA % |
3.04 | 2.99 | 2.96 | 3.17 | 3.14 | 3.11 | 2.57 | 2.63 | 2.62 | 2.93 | 3.06 | 4.03 | 3.76 | 3.35 | 3.59 | 3.15 | 4.46 | 3.16 | 3.24 | 3.58 | 2.26 | 2.85 | 2.29 | 2.52 | 3.09 | 1.72 | 2.83 | 1.38 | -0.09 | 2.47 | 1.68 | 3.55 | 6.11 | 4.67 | 5.28 | 3.99 | 2.66 | 3.06 | 4.81 | 7.19 | 8.22 | 9.20 | 16.67 | 16.54 | 16.91 | 20.03 | 17.89 | 18.28 | 21.51 | 18.44 | 20.00 | 20.41 | 17.42 | 9.31 | 3.29 | 2.52 |
ROCE % |
9.75 | 9.15 | 8.72 | 9.04 | 9.16 | 8.59 | 6.86 | 7.04 | 6.90 | 7.46 | 7.77 | 10.37 | 9.90 | 9.47 | 14.64 | 13.54 | 16.93 | 14.26 | 16.91 | 18.38 | 15.53 | 17.32 | 13.94 | 13.41 | 15.26 | 12.22 | 15.77 | 11.61 | 9.15 | 18.74 | 28.23 | 36.71 | 45.56 | 39.74 | 33.13 | 28.28 | 22.57 | 24.59 | 37.54 | 44.43 | 46.43 | 46.98 | 46.52 | 45.74 | 46.33 | 47.66 | 52.56 | 55.39 | 57.37 | 55.73 | 53.41 | 51.81 | 49.76 | 25.95 | 9.26 | 7.43 |
DSO |
49.5 | 49.0 | 46.2 | 47.1 | 43.6 | 45.4 | 45.1 | 44.4 | 44.5 | - | 22.6 | 43.0 | 45.2 | - | 42.7 | 45.2 | 40.9 | 45.7 | 56.8 | 38.4 | 47.7 | 46.7 | 49.2 | 49.2 | 49.7 | 48.1 | 49.5 | 46.7 | 55.5 | 50.3 | 52.4 | 50.1 | 49.0 | 45.7 | 45.5 | 48.2 | 47.8 | 48.7 | 47.7 | 40.5 | 49.3 | 49.2 | 50.2 | 51.2 | 53.3 | 19.0 | 55.1 | 54.5 | 58.0 | 19.9 | 57.6 | 57.4 | 59.0 | 20.0 | 57.4 | - |
DIO |
121.8 | 114.8 | 110.7 | 110.3 | 108.7 | 117.4 | 119.0 | 128.1 | 127.0 | - | 57.8 | 108.9 | 107.8 | - | 97.2 | 97.4 | 98.2 | 36.0 | 114.0 | 97.2 | 108.4 | 35.2 | 103.4 | 103.6 | 103.8 | 34.9 | 98.9 | 113.0 | 143.0 | 36.5 | 108.3 | 104.7 | 105.9 | 32.6 | 95.0 | 115.0 | 114.0 | 45.2 | 91.9 | 100.4 | 136.4 | 44.8 | 130.4 | 134.3 | 133.6 | 44.6 | 128.8 | 128.6 | 132.7 | 40.6 | 119.5 | 127.7 | 127.0 | 42.8 | 123.1 | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | 32.8 | - | - | - | 23.9 | 8.9 | - | - | 22.2 | 7.5 | - | - | 23.1 | 7.9 | - | - | 23.8 | 8.0 | - | - | 20.6 | 6.3 | - | - | 18.2 | 7.3 | - | - | 18.2 | 6.0 | - | - | 15.5 | 5.3 | - | - | 17.9 | 5.7 | - | - | 15.4 | 5.2 | - | - |
Operating Cycle |
171.2 | 163.8 | 156.9 | 157.4 | 152.4 | 162.8 | 164.1 | 172.5 | 171.5 | - | 80.4 | 151.9 | 153.0 | - | 139.9 | 142.6 | 139.1 | 81.7 | 170.8 | 135.6 | 156.1 | 81.9 | 152.6 | 152.8 | 153.5 | 83.0 | 148.3 | 159.7 | 198.4 | 86.8 | 160.7 | 154.8 | 154.8 | 78.3 | 140.6 | 163.2 | 161.9 | 93.8 | 139.6 | 140.8 | 185.7 | 94.0 | 180.6 | 185.5 | 186.8 | 63.6 | 183.9 | 183.1 | 190.8 | 60.5 | 177.1 | 185.1 | 186.0 | 62.8 | 180.6 | - |
Cash Conversion Cycle |
171.2 | 163.8 | 156.9 | 157.4 | 152.4 | 162.8 | 164.1 | 172.5 | 171.5 | - | 80.4 | 151.9 | 120.2 | - | 139.9 | 142.6 | 115.2 | 72.8 | 170.8 | 135.6 | 134.0 | 74.4 | 152.6 | 152.8 | 130.4 | 75.1 | 148.3 | 159.7 | 174.6 | 78.8 | 160.7 | 154.8 | 134.2 | 72.0 | 140.6 | 163.2 | 143.6 | 86.6 | 139.6 | 140.8 | 167.5 | 88.0 | 180.6 | 185.5 | 171.3 | 58.3 | 183.9 | 183.1 | 172.9 | 54.7 | 177.1 | 185.1 | 170.5 | 57.6 | 180.6 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Becton, Dickinson and Company, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
Baxter International
BAX
|
$ 20.17 | -1.01 % | $ 10.3 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 71.77 | -3.01 % | $ 3.61 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Repro Med Systems
KRMD
|
$ 5.59 | -1.5 % | $ 255 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 87.99 | 1.72 % | $ 1.98 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
OraSure Technologies
OSUR
|
$ 2.69 | -1.82 % | $ 200 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
ICU Medical
ICUI
|
$ 156.4 | 0.83 % | $ 3.81 B | USA |
 |
Predictive Oncology
POAI
|
$ 6.32 | -10.81 % | $ 34.5 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 8.79 | 2.76 % | $ 177 M | USA |
 |
Alcon
ALC
|
$ 79.46 | -0.27 % | $ 40.4 B |  Schweiz |
 |
AtriCure
ATRC
|
$ 40.49 | -2.33 % | $ 1.9 B | USA |
 |
electroCore
ECOR
|
$ 7.16 | 5.45 % | $ 39.5 K | USA |
 |
Masimo Corporation
MASI
|
$ 140.29 | 0.3 % | $ 7.48 B | USA |
 |
AngioDynamics
ANGO
|
$ 10.57 | -4.0 % | $ 432 M | USA |
 |
STERIS plc
STE
|
$ 267.85 | -0.15 % | $ 26.4 B | USA |
 |
The Cooper Companies
COO
|
$ 82.49 | 0.22 % | $ 16.4 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 0.58 | 0.9 % | $ 24.6 M | USA |
 |
Glaukos Corporation
GKOS
|
$ 120.57 | 5.32 % | $ 5.84 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 8.75 | 1.74 % | $ 181 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 169.75 | -1.33 % | $ 5.3 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 533.48 | -1.45 % | $ 189 B | USA |
 |
Merit Medical Systems
MMSI
|
$ 81.67 | 1.64 % | $ 4.75 B | USA |
 |
Utah Medical Products
UTMD
|
$ 60.9 | 1.05 % | $ 221 M | USA |
 |
Microbot Medical
MBOT
|
$ 2.19 | 5.02 % | $ 22.3 M |  Israel |
 |
Nephros
NEPH
|
$ 4.45 | 1.6 % | $ 46.2 M | USA |
 |
Milestone Scientific
MLSS
|
$ 0.29 | 0.99 % | $ 23.1 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 25.21 | 2.11 % | $ 4.34 B | USA |
 |
Pro-Dex
PDEX
|
$ 42.34 | 1.46 % | $ 139 M | USA |
 |
Pulse Biosciences
PLSE
|
$ 14.31 | 1.49 % | $ 687 M | USA |
 |
Repligen Corporation
RGEN
|
$ 165.1 | 2.11 % | $ 9.2 M | USA |
 |
ResMed
RMD
|
$ 258.93 | -0.68 % | $ 37.8 B | USA |
 |
BioLife Solutions
BLFS
|
$ 24.32 | -0.61 % | $ 1.12 B | USA |
 |
Stereotaxis
STXS
|
$ 2.74 | -1.44 % | $ 221 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.74 | 3.4 % | $ 22.2 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 20.89 | -0.38 % | $ 1.03 B | USA |
 |
Teleflex Incorporated
TFX
|
$ 103.47 | -1.09 % | $ 4.85 B | USA |
 |
West Pharmaceutical Services
WST
|
$ 264.03 | -5.5 % | $ 19.3 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 12.19 | -3.14 % | $ 2.48 B | USA |